Marcacuzco Quinto, Alberto Manrique Municio, Alejandro Jiménez Romero, Carlos Loinaz Segurola, Carmelo Calvo Pulido, Jorge Justo Alonso, Iago García-Sesma Pérez-Fuentes, Álvaro Abradelo de Usera, Manuel Cambra Molero, Félix Caso Maestro, Óscar Moreno González, Enrique
Trasplante hepático como tratamiento de la polineuropatía amiloidótica familiar en pacientes mayores de 60 años. [artículo] - Medicina clínica, 2015 - 144(9):385-8.
Formato Vancouver:
Marcacuzco Quinto AA, Manrique Municio A, Jiménez Romero LC, Loinaz Segurola C, Calvo Pulido J, Justo Alonso I et al. Trasplante hepático como tratamiento de la polineuropatía amiloidótica familiar en pacientes mayores de 60 años. Med Clin (Barc). 2015 May 8;144(9):385-8.
PMID: 24746275
Contiene 30 referencias
Background and objective: Familial amyloid polyneuropathy (FAP) is the most prevalent type of hereditary systemic amyloidosis. It is an autosomal dominant disease characterized by the deposition of an abnormal variant transthyretin. It has a worldwide distribution, with localized endemic areas in Portugal, Sweden and Japan. In Spain there is an endemic focus, located in Mallorca. Liver transplantation is the only curative option for patients with FAP. The aim of this study was to describe the clinical and demographic characteristics of patients transplanted with a diagnosis of PAF.
Material and method: Six patients with PAF underwent liver transplantation between April 1986 and December 2012.
Results: The mean age was 57.7+16 years, patients of Spanish origin were older than 60 years. All patients had progressive symptoms as mixed polyneuropathy. In 2 patients, combined heart-liver transplants sequentially were performed. Patient survival and graft was 80% at one, 3 and 5 years.
Conclusions: The only effective treatment for etiologic PAF is liver transplantation. Early detection is the key to the treatment and control, avoiding the irreversible organ damage.
Trasplante hepático como tratamiento de la polineuropatía amiloidótica familiar en pacientes mayores de 60 años. [artículo] - Medicina clínica, 2015 - 144(9):385-8.
Formato Vancouver:
Marcacuzco Quinto AA, Manrique Municio A, Jiménez Romero LC, Loinaz Segurola C, Calvo Pulido J, Justo Alonso I et al. Trasplante hepático como tratamiento de la polineuropatía amiloidótica familiar en pacientes mayores de 60 años. Med Clin (Barc). 2015 May 8;144(9):385-8.
PMID: 24746275
Contiene 30 referencias
Background and objective: Familial amyloid polyneuropathy (FAP) is the most prevalent type of hereditary systemic amyloidosis. It is an autosomal dominant disease characterized by the deposition of an abnormal variant transthyretin. It has a worldwide distribution, with localized endemic areas in Portugal, Sweden and Japan. In Spain there is an endemic focus, located in Mallorca. Liver transplantation is the only curative option for patients with FAP. The aim of this study was to describe the clinical and demographic characteristics of patients transplanted with a diagnosis of PAF.
Material and method: Six patients with PAF underwent liver transplantation between April 1986 and December 2012.
Results: The mean age was 57.7+16 years, patients of Spanish origin were older than 60 years. All patients had progressive symptoms as mixed polyneuropathy. In 2 patients, combined heart-liver transplants sequentially were performed. Patient survival and graft was 80% at one, 3 and 5 years.
Conclusions: The only effective treatment for etiologic PAF is liver transplantation. Early detection is the key to the treatment and control, avoiding the irreversible organ damage.
